AZD2281: Phase II started

AZN's KuDOS Pharmaceuticals Ltd. subsidiary began the open-label international Phase II ICEBERG trial of oral AZD2281 in 40 patients with advanced, BRCA1- or BRCA2-positive breast cancer. Patients wil...